Publications by authors named "S T Daneshmand"
Treatment options for recurrent high-risk non-muscle-invasive bladder cancer (HR NMIBC) and muscle-invasive bladder cancer (MIBC) are limited, highlighting a need for clinically effective, accessible, and better-tolerated alternatives. In this review we examine the clinical development program of TAR-200, a novel targeted releasing system designed to provide sustained intravesical delivery of gemcitabine to address the needs of patients with NMIBC and of those with MIBC. We describe the concept and design of TAR-200 and the clinical development of this gemcitabine intravesical system in the SunRISe portfolio of studies.
View Article and Find Full Text PDFObjectives: To reassess the role of primary retroperitoneal lymph node dissection (RPLND) in patients with marker-negative non-seminomatous germ cell tumour (NSGCT) clinical stage (CS) 2a, to explore results in patients with CS 2b and to evaluate surgical methods, recurrence, and adjuvant chemotherapy indications.
Materials And Methods: Data from 17 institutions were collected, comprising 305 men who underwent primary RPLND for CS 2 NSGCT. Regression analyses were conducted to predict histology in the RPLND specimen and disease-free survival (DFS).
Background: Whether extended lymphadenectomy is associated with improved disease-free and overall survival, as compared with standard lymphadenectomy, among patients with localized muscle-invasive bladder cancer undergoing radical cystectomy is unclear.
Methods: We randomly assigned, in a 1:1 ratio, patients with localized muscle-invasive bladder cancer of clinical stage T2 (confined to muscle) to T4a (invading adjacent organs) with two or fewer positive nodes (N0, N1, or N2) to undergo bilateral standard lymphadenectomy (dissection of lymph nodes on both sides of the pelvis) or extended lymphadenectomy involving removal of common iliac, presciatic, and presacral nodes. Randomization was performed during surgery and stratified according to the receipt and type of neoadjuvant chemotherapy, tumor stage (T2 vs.
Article Synopsis
- - Testicular germ cell tumors (TGCTs) are rare but their incidence is rising globally, with varying rates across different regions and ethnicities. This review examines the changing patterns and identifies risk factors associated with TGCT.
- - The research included a systematic review of 53 reports, revealing that genetic predisposition accounts for about 44% of TGCT heritability, as well as various risk factors like in utero chemical exposure and behavioral issues such as marijuana use.
- - Conclusions suggest that the increase in TGCT cases may be linked to socioeconomic changes and migration, necessitating further research and better screening programs to address the rising incidence.
Article Synopsis
- - The study analyzed genomic and transcriptomic data from 138 germ cell tumors to find out why some tumors resist treatment with cisplatin, a common chemotherapy drug.
- - They focused on specific genetic mutations (like KRAS, TP53, and KIT) and patterns in gene copies that might contribute to this resistance, observing that certain mutations were more common in primary tumors compared to metastatic ones.
- - The research found that tumors with platinum-resistant alterations had lower transcriptomic scores linked to sensitivity to cisplatin, indicating a possible connection between these genetic changes and treatment resistance.